Review Article

Oncolytic Virotherapy for Breast Cancer Treatment

Author(s): Samia M. O`Bryan and J. Michael Mathis*

Volume 18, Issue 4, 2018

Page: [192 - 205] Pages: 14

DOI: 10.2174/1566523218666180910163805


Breast cancer continues to be a leading cause of mortality among women. While at an early stage, localized breast cancer is easily treated; however, advanced stages of disease continue to carry a high mortality rate. The discrepancy in treatment success highlights that current treatments are insufficient to treat advanced-stage breast cancer. As new and improved treatments have been sought, one therapeutic approach has gained considerable attention. Oncolytic viruses are uniquely capable of targeting cancer cells through intrinsic or engineered means. They come in many forms, mainly from four major virus groups as defined by the Baltimore classification system. These vectors can target and kill cancer cells, and even stimulate immunotherapeutic effects in patients. This review discusses not only individual oncolytic viruses pursued in the context of breast cancer treatment but also the emergence of combination therapies with current or new therapies, which has become a particularly promising strategy for treatment of breast cancer. Overall, oncolytic virotherapy is a promising strategy for increased treatment efficacy for advanced breast cancer and consequently provides a unique platform for personalized treatments in patients.

Keywords: Breast cancer, Clinical trials, Oncolytic, Preclinical, Vectors, Virotherapy, Viruses.

© 2024 Bentham Science Publishers | Privacy Policy